Last $62.76 USD
Change Today -0.87 / -1.37%
Volume 493.1K
PRXL On Other Exchanges
Symbol
Exchange
NASDAQ GS
Stuttgart
As of 8:10 PM 10/22/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

195 West Street

Waltham, MA 02451

United States

Phone: 781-487-9900

Fax: 781-487-0525

PAREXEL International Corporation, a biopharmaceutical services company, provides clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology products and services to the worldwide pharmaceutical, biotechnology, and medical device industries. The company’s product and service offerings include clinical trials management, observational studies and patient/disease registries, data management, biostatistical analysis, epidemiology, health economics/outcomes research, pharmacovigilance, medical communications, clinical pharmacology, patient recruitment, clinical supply and drug logistics, post-marketing surveillance, regulatory and product development and commercialization consulting, health policy and reimbursement and market access consulting, medical imaging services, regulatory information management (RIM) solutions, ClinPhone randomization and trial supply management services (ClinPhone RTMS), electronic data capture systems (EDC), clinical trial management systems (CTMS), Web-based portals, systems integration, patient diary applications, and other product development tools and services. The company conducts business in healthcare markets worldwide, including the United States (U.S.), Argentina, Australia, Austria, Belarus, Belgium, Bosnia, Brazil, Canada, Chile, China, Colombia, Croatia, the Czech Republic, Denmark, Estonia, Finland, France, Georgia, Germany, Hungary, India, Indonesia, Ireland, Israel, Italy, Japan, Korea, Latvia, Lithuania, Malaysia, Mexico, the Netherlands, Norway, Peru, the Philippines, Poland, Romania, Russia, Serbia, Singapore, Slovakia, South Africa, Spain, Sweden, Taiwan, Thailand, Turkey, Ukraine, the United Kingdom (U.K.), and Vietnam. Segments The company has three segments: Clinical Research Services (CRS), PAREXEL Consulting Services (PC), and PAREXEL Informatics (PI). Clinical Research Services This segment offers complete services for the design, initiation and management of clinical trial programs, a critical element in obtaining regulatory approval for biopharmaceutical products. The company has performed services in connection with clinical trials in most therapeutic areas, including oncology, cardiology, infectious diseases, neurology, allergy/immunology, endocrinology/metabolism, gastroenterology, obstetrics/gynecology, orthopedics, pediatrics, psychiatry, pulmonology, rheumatology, dermatology, genitourinary, ophthalmology, and transplantation. Its multi-disciplinary clinical trials group examines a product’s existing preclinical and clinical data to design clinical trials to provide evidence of the product’s safety and efficacy. CRS can manage various aspects of clinical trials including study protocol design; Case Report Form (CRF) design; site and investigator recruitment; patient enrollment; study monitoring and data collection; data management; biostatistics and programming; report writing; medical services; project management; and clinical logistics. Clinical trials and observational studies are monitored and conducted by CRS in adherence with Good Clinical Practice (GCP) and Good Pharmacoepidemiological Practice (GPP), respectively. Early Phase The Early Phase business unit of CRS includes the early stages of clinical testing, when a product is first evaluated to assess the safety and efficacy of the product. These tests vary from ‘first-in-man’ to ‘dose-ranging’ to ‘proof of concept’ studies in Phases I and IIa of development. The Early Phase business unit of CRS offers clients a one-stop service where studies are performed in healthy volunteers, as well as in patients of various disease populations. The support services include project and program management, drug development consulting, medical writing, handling of investigational products, data management, and biostatistical and bioanalytical services. Its international network of Early Phase operations includes operations in Berlin, Germany; Baltimore, Maryland (U.S.); Glendale, California (U.S.); Bloemfontein, South Africa; and Harrow, the United Kingdom. With these locations, the Early Phase business unit offers clinical pharmacology

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRXL:US $62.76 USD -0.87

PRXL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Charles River Laboratories International Inc $61.83 USD -0.40
GFK SE €31.80 EUR +0.461
ICON PLC $57.05 USD +0.14
Advisory Board Co/The $49.33 USD -0.34
WuXi PharmaTech Cayman Inc $36.30 USD -0.13
View Industry Companies
 

Industry Analysis

PRXL

Industry Average

Valuation PRXL Industry Range
Price/Earnings 28.3x
Price/Sales 1.9x
Price/Book 6.0x
Price/Cash Flow 16.6x
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PAREXEL INTERNATIONAL CORP, please visit www.parexel.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.